Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use

Daikos, GL; Skiada, A; Pavleas, J; Vafiadi, C; Salatas, K; Tofas, P; Tzanetou, K; Markogiannakis, A; Thomopoulos, G; Vafiadi, I; Petrikkos, G

dc.contributor.author	Daikos, GL	en
dc.contributor.author	Skiada, A	en
dc.contributor.author	Pavleas, J	en
dc.contributor.author	Vafiadi, C	en
dc.contributor.author	Salatas, K	en
dc.contributor.author	Tofas, P	en
dc.contributor.author	Tzanetou, K	en
dc.contributor.author	Markogiannakis, A	en
dc.contributor.author	Thomopoulos, G	en
dc.contributor.author	Vafiadi, I	en
dc.contributor.author	Petrikkos, G	en
dc.date.accessioned	2014-03-01T01:34:35Z
dc.date.available	2014-03-01T01:34:35Z
dc.date.issued	2010	en
dc.identifier.issn	1120-009X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/20760
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-78650245529&partnerID=40&md5=163caefe3be673a84ad79dfd808511e5	en
dc.subject	Colistin	en
dc.subject	Dosing regimens	en
dc.subject	Pseudomonas aeruginosa	en
dc.subject	Serum bactericidal activity	en
dc.subject.classification	Oncology	en
dc.subject.classification	Pathology	en
dc.subject.classification	Pharmacology & Pharmacy	en
dc.subject.other	colistimethate	en
dc.subject.other	adult	en
dc.subject.other	aged	en
dc.subject.other	article	en
dc.subject.other	bactericidal activity	en
dc.subject.other	blood sampling	en
dc.subject.other	clinical article	en
dc.subject.other	concentration response	en
dc.subject.other	controlled study	en
dc.subject.other	dosage schedule comparison	en
dc.subject.other	drug dose regimen	en
dc.subject.other	female	en
dc.subject.other	high performance liquid chromatography	en
dc.subject.other	human	en
dc.subject.other	male	en
dc.subject.other	maximum plasma concentration	en
dc.subject.other	minimum inhibitory concentration	en
dc.subject.other	nonhuman	en
dc.subject.other	optimal drug dose	en
dc.subject.other	Pseudomonas aeruginosa	en
dc.subject.other	serum	en
dc.subject.other	Aged	en
dc.subject.other	Anti-Bacterial Agents	en
dc.subject.other	Blood Bactericidal Activity	en
dc.subject.other	Colistin	en
dc.subject.other	Critical Illness	en
dc.subject.other	Dose-Response Relationship, Drug	en
dc.subject.other	Female	en
dc.subject.other	Humans	en
dc.subject.other	Intensive Care Units	en
dc.subject.other	Male	en
dc.subject.other	Microbial Sensitivity Tests	en
dc.subject.other	Middle Aged	en
dc.subject.other	Pseudomonas aeruginosa	en
dc.subject.other	Pseudomonas Infections	en
dc.title	Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Although colistin methanesulfonate (CMS) has been used extensively in critically ill patients infected with multidrug-resistant organisms, the optimum dosing regimen remains to be determined. Herein, we examined the pharmacokinetics of three different dosing regimens of CMS, 3 million units every 8 h (regimen A), 4.5 million units every 12 h (regimen B), 9 million units every 24 h (regimen C) and evaluated the bactericidal activity of serum containing various concentrations of colistin against Pseudomonas aeruginosa with a minimum inhibitory concentration (MIC) of 1 μg/ml. The means ± SE serum Cmax of colistin for regimens A, B, and C were 3.34±0.35, 2.98±0.27, and 5.63±0.87 μg/ml, respectively. All serum samples containing colistin >4 μg/ml (serum concentration/MIC >4) eliminated P. aeruginosa whereas only 40% of samples containing colistin <4 μg/ml resulted in complete bacterial killing. These findings indicate that the currently used dosing regimens might not provide the most effective therapy with CMS and justify administering larger dosages in longer intervals. © E.S.I.F.T. srl.	en
heal.publisher	ESIFT SRL	en
heal.journalName	Journal of Chemotherapy	en
dc.identifier.isi	ISI:000283476300006	en
dc.identifier.volume	22	en
dc.identifier.issue	3	en
dc.identifier.spage	175	en
dc.identifier.epage	178	en